Related Experiment Video
Updated: Apr 14, 2026
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Selective Targeting of the TPX2 Site of Importin-α Using Fragment-Based Ligand Design
Rhian S Holvey1, Eugene Valkov2, David Neal3
1Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW (UK).
Abstract:
Protein-protein interactions are difficult therapeutic targets, and inhibiting pathologically relevant interactions without disrupting other essential ones presents an additional challenge. Herein we report how this might be achieved for the potential anticancer target, the TPX2-importin-α interaction. Importin-α is a nuclear transport protein that regulates the spindle assembly protein TPX2. It has two binding sites--major and minor-to which partners bind. Most nuclear transport cargoes use the major site, whereas TPX2 binds principally to the minor site. Fragment-based approaches were used to identify small molecules that bind importin-α, and crystallographic studies identified a lead series that was observed to bind specifically to the minor site, representing the first ligands specific for this site. Structure-guided synthesis informed the elaboration of these fragments to explore the source of ligand selectivity between the minor and major sites. These ligands are starting points for the development of inhibitors of this protein-protein interaction.
Insights
Researchers developed novel small molecules targeting the TPX2-importin-α interaction, a potential anticancer target. These molecules selectively bind to importin-α's minor site, offering a new strategy for therapeutic intervention.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Protein-protein interactions (PPIs) are challenging therapeutic targets.
- Inhibiting specific PPIs, like TPX2-importin-α, is crucial for anticancer drug development.
- Importin-α, a nuclear transport protein, interacts with TPX2 at its minor binding site.
Purpose of the Study:
- To identify selective inhibitors for the TPX2-importin-α interaction.
- To develop novel therapeutic strategies targeting specific PPIs.
- To explore the development of small molecules for cancer therapy.
Main Methods:
- Fragment-based drug discovery approaches were employed.
- Crystallographic studies were used to analyze ligand binding.
- Structure-guided synthesis was utilized to optimize lead compounds.
Main Results:
- Identified small molecules that bind specifically to the minor site of importin-α.
- Developed the first known ligands selective for the importin-α minor site.
- Elaborated fragments to understand ligand selectivity between major and minor binding sites.
Conclusions:
- The identified ligands are promising starting points for developing inhibitors of the TPX2-importin-α interaction.
- This work provides a foundation for targeting specific PPIs with high selectivity.
- The findings contribute to the advancement of anticancer drug discovery efforts.
